Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ORMP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOramed sells Oratech subsidiary to Lifeward for 50% equity stake, invests $9M in convertible notes
Filed March 31, 2026 · Period ending March 25, 2026 · ~1 min read
Key Changes
-
high
Oramed divested wholly-owned subsidiary Oratech to Lifeward for ~50% equity stake (1.25M shares, 1M pre-funded warrants at $0.0001, and 1.3M warrants at $5.40), transforming from subsidiary owner to major Lifeward shareholder
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Simultaneously invested $9M in Lifeward senior secured convertible notes (convertible at $5.40/share) plus warrants for 1.67M additional shares at $5.40, becoming both major shareholder and creditor
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Secured 4% revenue share on Lifeward's ReWalk exoskeleton product sales for up to 10 years, terminating earlier if maximum amount reached or Lifeward market cap hits $200M
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
Summary
Oramed executed a strategic pivot on March 25, 2026, selling its Oratech subsidiary to medical device company Lifeward in exchange for approximately 50% ownership of Lifeward through a combination of ordinary shares, pre-funded warrants, and additional warrants. The transaction fundamentally reshapes Oramed's business model from operating a pharmaceutical subsidiary to holding a controlling equity position in an exoskeleton device manufacturer. The company doubled down on this bet by simultaneously investing $9 million in Lifeward convertible notes and warrants, positioning itself as both Lifeward's largest shareholder and a senior creditor.
The revenue-sharing arrangement provides a hedge through ongoing payments tied to ReWalk product sales, though these terminate if Lifeward's market cap reaches $200 million—suggesting Oramed expects significant upside in the equity position to compensate for lost revenue share. Retail holders should recognize this as a complete business transformation: Oramed has effectively converted a pharmaceutical asset into concentrated exposure to Lifeward's commercial success in the medical device sector.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Oramed closed sale of subsidiary Oratech to Lifeward for equity stake and revenue share, plus $9M convertible note investment in Lifeward.
Added in current filing · verify on EDGAR →
On March 25, 2026, Lifeward completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement. At the closing of the Share Purchase Transaction, Lifeward issued to the Company an aggregate of (i) 1,250,363 Lifeward Ordinary Shares, (ii) 1,006,113 Pre-Funded Warrants at an exercise price equal to $0.0001 per share, and (iii) Share Purchase Warrants to purchase up to 1,296,296 Lifeward Ordinary Shares at an initial exercise price equal to $5.40 per share (subject to certain adjustments as set forth in the Share Purchase Warrants).
Oramed divested its wholly-owned subsidiary Oratech Pharma to Lifeward Ltd., receiving in exchange approximately 49.99% of Lifeward's equity through a combination of ordinary shares, pre-funded warrants exercisable at $0.0001 per share, and additional warrants exercisable at $5.40 per share. This transaction transforms Oramed from owning a subsidiary to holding a significant equity position in Lifeward, a medical device company focused on exoskeleton products.
Event · Item 2.01 — Completion of Acquisition or Disposition of Assets
Oramed disclosed completion of an acquisition or disposition, with details incorporated by reference from Item 1.01.
Added in current filing · verify on EDGAR →
Item 2.01 Completion of Acquisition or Disposition of Assets
The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
The 8-K discloses completion of an acquisition or disposition of assets under Item 2.01, but provides no details in this section. All material information is incorporated by reference from Item 1.01, which is not included in the provided filing text. Without access to Item 1.01, the nature, size, counterparty, and financial impact of the transaction cannot be determined.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify